Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
8.77
-0.45 (-4.88%)
At close: Sep 25, 2026, 4:00 PM EDT
8.82
+0.05 (0.57%)
After-hours: Sep 25, 2026, 7:58 PM EDT
Q32 Bio Revenue
In the year 2025, Q32 Bio had annual revenue of $53.74M.
Revenue (ttm)
$53.74M
Revenue Growth
n/a
P/S Ratio
4.86
Revenue / Employee
$2,442,591
Employees
22
Market Cap
261.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.74M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 61.21M |
| Invivyd | 58.37M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 21.67M |
| Lineage Cell Therapeutics | 13.08M |
| Palisade Bio | 500.00K |
| Vicore Pharma Holding AB | 412.09K |
QTTB News
- 6 days ago - Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 - PRNewsWire
- 12 days ago - Q32 Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 13 days ago - Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D. - PRNewsWire
- 18 days ago - Q32 Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 19 days ago - Q32 Bio Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 26 days ago - Q32 Bio to Participate in Upcoming September Investor Conferences - PRNewsWire
- 4 weeks ago - Q32 Bio initiated with an Overweight at Morgan Stanley - TheFly
- 7 weeks ago - Q32 Bio Quarterly report: Q2 2026 - Filings